DDInter1939 DDInter1435
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting. A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Vinorelbine {u} (Compound) resembles {v} (Compound) Vincristine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinorelbine {u} (Compound) treats {v} (Disease) hematologic cancer
Vinorelbine {u} (Compound) binds {v} (Gene) TUBB4B
Vinorelbine {u} (Compound) upregulates {v} (Gene) LAMC2
Vinorelbine {u} (Compound) is included by {v} (Pharmacologic Class) Vinca Alkaloids
Vinorelbine {u} (Compound) downregulates {v} (Gene) IARS2
Vinorelbine {u} (Compound) causes {v} (Side Effect) Angina pectoris
Vinorelbine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Vinorelbine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Vinorelbine (Compound) resembles Vincristine (Compound)
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine
Vinorelbine (Compound) treats hematologic cancer (Disease)
Vinorelbine (Compound) binds TUBB4B (Gene)
Vinorelbine (Compound) upregulates LAMC2 (Gene)
Vinorelbine (Compound) is included by Vinca Alkaloids (Pharmacologic Class)
Vinorelbine (Compound) downregulates IARS2 (Gene)
Vinorelbine (Compound) causes Angina pectoris (Side Effect)
Vinorelbine may cause a minor interaction that can limit clinical effects when taken with Modafinil
Vinorelbine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin